Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma

Inclusion Criteria

• Biopsy-proven KS involving skin with or without visceral involvement either newly diagnosed or refractory to or intolerant of one or more prior therapies
• Patients must have cutaneous lesion(s) amenable to four 3 mm tumor biopsies during the study (either 4 separate lesions measuring > 4 mm each OR 2 separate lesions measuring > 8 mm each) and at least five additional lesions measurable for assessment with no improvement over the past month
• Serologic documentation of HIV infection by any of the Food and Drug Administration (FDA)-approved tests
• Karnofsky performance status >= 60%
• Hemoglobin >= 8 g/dL
• Absolute neutrophil count (ANC) >= 1, 000 cells/mm^3
• Platelet count >= 100,000/mm^3
• Calculated (method of Cockcroft-Gault) creatinine clearance (CrCl) >= 60 mL/min in the Phase I and CrCl >= 30 mL/min in the Phase II (creatinine clearance may also be obtained by the 24-hour collection method at the investigator's discretion)
• Total bilirubin should be = = 3 months
• Ability and willingness to give informed consent
• Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10 - 14 days prior to and again within 24 hours prior to starting Cycle 1 of lenalidomide; further, they must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control: one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before starting lenalidomide, during receipt of lenalidomide, and 28 days after discontinuation of lenalidomide; FCBP must also agree to ongoing pregnancy testing; men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy; all patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure
• Patients must, in the opinion of the investigator, be capable of complying with the protocol
• All patients must be on antiretroviral therapy for HIV infection with CD4 count > 50/mm^3 and viral load = 200/mL), then antiretroviral therapy must be adjusted to a less toxic regimen allowing for optimal viral suppression and must demonstrate stability for at least 12 weeks prior to study entry
• Patients with any history of pulmonary embolism (PE) or deep venous thrombosis (DVT) or predisposing clotting risk factors must be on anticoagulation at therapeutic dosing

Exclusion Criteria

• Concurrent, acute, active opportunistic infection other than oral thrush or genital herpes within 14 days of enrollment
• Patients for whom front-line cytotoxic therapy is indicated (i.e. symptomatic visceral or pulmonary KS or symptomatic KS impairing functional status)
• Concurrent neoplasia requiring cytotoxic therapy
• Acute treatment for an infection (other than oral thrush or genital herpes) or other serious medical illness within 14 days of study entry
• Anti-neoplastic treatment for KS (including chemotherapy, radiation therapy, local therapy including topical 5-FU, biological therapy, or investigational therapy) within four weeks of study entry
• Any steroid treatment except for that required for replacement therapy in adrenal insufficiency or inhaled steroids for the treatment of asthma
• Patient is = 2,000 copies/mL
• Patients on estrogen therapy unless also on therapeutic anticoagulation